Prognostically relevant natural killer cell-mediated immunoediting in acute myeloid leukemia by unknown
POSTER PRESENTATION Open Access
Prognostically relevant natural killer cell-mediated
immunoediting in acute myeloid leukemia
Christopher J Chan1,2*, Daniel M Andrews2,3, Mark J Smyth2,3,4, Paul J Neeson2,3, David S Ritchie2,3
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
Natural Killer (NK) cells contribute to the control of
cancer through immunosurveillance and may influence
phenotypic sculpting of cancer through immunoediting.
NK cells may also contribute to the control of hematologi-
cal malignancies such as acute myeloid leukemia (AML)
following allogeneic stem cell transplantation. However,
no studies have shown direct clinical evidence that sup-
ports immunoediting by NK cells in AML at presentation,
or whether activating ligand expression at diagnosis serves
as a prognostic indicator of survival. We now show that at
diagnosis, expression of NK cell ligands on AML blast
populations is heterogeneous. Furthermore, expression of
multiple activating ligands is associated with favorable
cytogenetics and improved leukemia-free survival. In ana-
lyses of paired diagnostic and relapse samples, AML blasts
exhibiting lower expression of activating ligands were
selectively increased at relapse, indicating that NK cell-
mediated blast immunoediting occurred prior to AML
escape. Therapeutically, NK cell activating ligands could
be upregulated on AML by in vitro treatment with borte-
zomib that enhanced NK cell-mediated cytotoxicity. Thus,
diagnostic analyses of the expression of NK cell activating
ligands in AML could be used to design therapeutic
approaches for specific patients, and agents that stimulate
NK cell function by restoring NK cell ligand expression
may be appropriate to eliminate minimal residual disease
and reduce risk of relapse.
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